Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + Backbone Treatments in Multiple Myeloma
NCT02036502Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of pembrolizumab in multiple myeloma (MM) (8 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 72.7 months and 1 more. Started Feb 2014; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02036502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036502.